CRISPR Therapeutics AG (CRSP) Financials: Revenue & Earnings
CRSP$55.07+0.96 +1.77%
$5.32B
Market Cap
-10.30
P/E
12.46
Forward P/E
40
Score
CRISPR Therapeutics AG (CRSP) Financials: Revenue & Earnings
CRSP price $55.07 +0.96 +1.77%
- Ticker
- CRSP
- Price
- $55.07
- Change
- +0.96 +1.77%
- Market cap ?
- $5.32B
- P/E ?
- -10.30
- Forward P/E ?
- 12.46
- Dividend yield ?
- 0.00%
- Beta ?
- 1.76
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 40
- Value
- 55
- Quality
- 26
- Growth
- 38
Stocklytics score rationale: value 55, quality 26, growth 38.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 5164000 | 40997000 | 3124000 | 289590000 | 719000 | 913081000 | 436000 | 370000000 | 35000000 | 3510000 |
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates…
Earnings and financials
CRISPR Therapeutics AG (CRSP) trades at $55.07, with a market cap of $5.32B and a trailing P/E of -10.30. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 5164000 | 40997000 | 3124000 | 289590000 | 719000 | 913081000 | 436000 | 370000000 | 35000000 | 3510000 |
Insights · Dividends · Forecast · Financials · Learn